The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review

Lyman, Gary H.; Allcott, Kim; Garcia, Jacob; Stryker, Scott; Li, Yanli; Reiner, Maureen; Weycker, Derek

doi:10.1007/s00520-017-3703-y

Cited by 44 publications

(37 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on clinical trial data, the panel recommends that pegfilgrastim be administered the day following myelosuppressive chemotherapy. 65 The rationale for not giving same-day pegfilgrastim is the potential for exacerbation of neutropenia resulting from stimulation of hematopoietic progenitor cells at the time of cytotoxic chemotherapy active in dividing cells, resulting in loss of the progenitors. 65,66 Based on review of these data, the panel endorsed the next-day administration of pegfilgrastim biosimilars.…”

Section: Nccn Recommendations For Management Of Fnmentioning

confidence: 99%

“…65 The rationale for not giving same-day pegfilgrastim is the potential for exacerbation of neutropenia resulting from stimulation of hematopoietic progenitor cells at the time of cytotoxic chemotherapy active in dividing cells, resulting in loss of the progenitors. 65,66 Based on review of these data, the panel endorsed the next-day administration of pegfilgrastim biosimilars. Administration of pegfilgrastim or pegfilgrastim biosimilars up to 3 to 4 days after myelosuppressive chemotherapy is also reasonable based on trials of filgrastim.…”

Section: Nccn Recommendations For Management Of Fnmentioning

confidence: 99%

See 1 more Smart Citation

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020

Becker

Griffiths²,

Alwan

et al. 2020

Journal of the National Comprehensive Cancer Network

Self Cite

View full text Add to dashboard Cite

Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.

show abstract

Section: Nccn Recommendations For Management Of Fnmentioning

confidence: 99%

Section: Nccn Recommendations For Management Of Fnmentioning

confidence: 99%

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020

Becker

Griffiths²,

Alwan

et al. 2020

Journal of the National Comprehensive Cancer Network

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similar findings were reported in follow-up studies using private healthcare claims data spanning 2010-2015 (OR ¼ 1.3, 95% CI 1.2-1.4) and using Medicare claims data (OR ¼ 1.3, 95% CI 1.2-1.4) 64,65 . A recent systematic review of the literature on this topic concluded that the literature supports "administration of pegfilgrastim to patients at least 1 d after the completion of a chemotherapy cycle" 66 .…”

Section: The 2010smentioning

confidence: 99%

Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years

Edelsberg

Weycker

Bensink

et al. 2019

Current Medical Research and Opinion

Self Cite

View full text Add to dashboard Cite

Filgrastim prophylaxis, both primary and secondary, was rapidly incorporated into clinical practice in the 1990s. When pegfilgrastim became available in 2002, it quickly replaced filgrastim as the colonystimulating factor (CSF) of choice for prophylaxis. Use of prophylaxis increased markedly in the first decade of this century and has stabilized during the present decade. Data concerning real-world CSF prophylactic practice patterns are limited but suggest that both primary and secondary prophylaxis are common, and that use is frequently inappropriate according to guidelines. The extent of inappropriate use is controversial, as are issues concerning the cost-effectiveness of prophylaxis versus no prophylaxis and the cost-effectiveness of primary prophylaxis versus secondary prophylaxis. Nevertheless, CSF prophylaxis is firmly established as a valuable adjunct to chemotherapy and will almost certainly continue to be widely used for the foreseeable future. In this article, we chronicle the use and impact of CSF prophylaxis in US patients receiving myelosuppressive chemotherapy for nonmyeloid malignancies. We emphasize the interplay of expert opinion, clinical evidence, and economic factors in shaping the use of CSFs in clinical practice over time, and, with the recent introduction of new CSF agents and options, we aim to provide useful clinical and economic information for healthcare decision makers. ARTICLE HISTORY

show abstract

“…In our study, we prescribed long-acting G-CSF according to the instruction booklet with 6 mg at 48 hours after chemotherapy. Such administration was reasonable according to a systematic review27 and consensus guidance recommendations 28. Patients who received pegfilgrastim on the day after chemotherapy had less severe and shorter suppression of the ANC than patients who received pegfilgrastim on the same day as chemotherapy 29.…”

Section: Discussionmentioning

confidence: 99%

The prophylactic effects of long-acting granulocyte colony-stimulating factor for febrile neutropenia in newly diagnosed patients with epithelial ovarian cancer: a randomised controlled study

et al. 2019

BMJ Support Palliat Care

View full text Add to dashboard Cite

ObjectiveThis study explored the prophylactic effects of long-acting granulocyte colony-stimulating factor (G-CSF) for febrile neutropenia (FN) in newly diagnosed patients with epithelial ovarian cancer (EOC).MethodsPatients were randomised into a study group (long-acting G-CSF for all chemotherapy cycles) and a control group (short-acting G-CSF for first cycle and treatment per physician discretion for subsequent cycles) at a ratio of 1:2. The incidences of FN and myelosuppression and the number of clinical visits, medication doses, complete blood count (CBC) tests and adverse events were compared between the two groups. A regression model was used to determine the risk factors for FN.ResultsFrom 30 November 2018 to 1 April 2019, 84 cases were included in the final analysis; there were 24 (28.6%) and 60 (71.4%) patients in the study and control groups, respectively, and 605 chemotherapy cycles. The study group or chemotherapy cycles utilising long-acting G-CSF had significantly fewer utilisations and doses of short-acting G-CSF; clinical visits; CBC tests; and incidences of FN and myelosuppression; and less G-CSF-associated pain. The utilisation of G-CSF was the only independent factor for FN in a binary regression model.ConclusionLong-acting G-CSF could effectively reduce the incidences of FN and myelosuppression and had mild adverse effects in newly diagnosed patients with EOC receiving chemotherapy.Trial registration number NCT03740464.

show abstract

The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review

Abstract: Data from multiple publications support administration of pegfilgrastim at least 1 day after chemotherapy.

Cited by 44 publications

References 28 publications

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020

Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years

The prophylactic effects of long-acting granulocyte colony-stimulating factor for febrile neutropenia in newly diagnosed patients with epithelial ovarian cancer: a randomised controlled study

Contact Info

Product

Resources

About